A part of Watch Media

MedWatchWednesday4 October 2023

  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
MedWatchWednesday4 October 2023
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Hearing health

WS Audiology launches new platform and top products

New product platform under the Signia brand builds on known technology that WSA believes sets them apart from the competition. 
Maarten Barmentlo, marketingdirektør i WS Audiology | Photo: Ws Audiology / Pr
Maarten Barmentlo, marketingdirektør i WS Audiology | Photo: Ws Audiology / Pr
by ALBERT RØNNING-ANDERSSON

WS Audiology is launching a new product platform under the Signia brand, formerly part of Sivantos.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Related articles:

  • Eric Bernard, adm. direktør i WS Audiology | Photo: Ws Audiology / Pr

    WS Audiology varsler ny produktplatform ”meget snart”

    For subscribers

  • Photo: WS Audiology / PR

    WSA venter med nye produktplatforme – ser stadig muligheder i eksisterende

    For subscribers

  • Photo: WS Audiology / PR

    WSA klar med genopladelig Widex-platform inden for kommende uger

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Photo: Tom Little
Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.
  • FDA to review Novo Nordisk drug for rare metabolic disease
  • Huge acquisition scores Novo Nordisk an FDA-ready treatment

For subscribers



Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Photo: Liselotte Plenov / Fotorummet / Pr
Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers



Photo: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers


Photo: Mike Segar/Reuters/Ritzau Scanpix
Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug


Photo: Yuriko Nakao/Reuters/Ritzau Scanpix
Medtech

Olympus appoints new chief medical officer

For subscribers


Photo: Alexander Heinl/AP/Ritzau Scanpix
Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

For subscribers


  • Vaccine breakthrough behind mRNA shots wins Nobel Prize

    The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.

    For subscribers


  • Photo: Ws Audiology / Pr

    WS Audiology hires new chief technology officer from car manufacturer

    He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.

    For subscribers


  • Photo: Tom Little

    Novo Nordisk files lawsuit against US authorities ahead of price negotiation

    The litigation is the latest in a long line of industry lawsuits related to price negotiations.

    For subscribers


  • Photo: Mike Segar

    FDA rejects atopic dermatitis drug lebrikizumab

    Eli Lilly had expected a launch this year.

    For subscribers


  • The FDA has updated the package label of Novo Nordisk's diabetes drug, Ozempic, with a warning about intestinal blockage disorder as a possible side effect. | Photo: Tom Little/Reuters/Ritzau Scanpix

    FDA updates Novo Nordisk's Ozempic drug label with side effect alert

    The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.

    For subscribers


  • Photo: Anushree Fadnavis/Reuters/Ritzau Scanpix

    Country Manager: Indians will have to wait for Wegovy until 2026

    Up to 40% of the female population aged 30-49 in India is overweight.

    For subscribers


Further reading

Foto: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Sonova and Demant slightly increased market share with US veterans in August

GN Hearing declined for the second month in a row.

For subscribers



Photo: Tom Little
Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers



Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Photo: Liselotte Plenov / Fotorummet / Pr
Pharma & biotech

Fujifilm expands management with former Leo executive

The contract manufacturer has hired a chief people officer with immediate effect.

For subscribers


Photo: Mike Segar/Reuters/Ritzau Scanpix
Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.


The hearing group WS Audiology, the result of the 2019 merger between Widex and Sivantos, has no plans to integrate the two hearing aid platforms from each of the respective companies before the merger. | Photo: Ws Audiology / Pr
Hearing health

WS Audiology has no plans of merging product platforms

Hearing health group WS Audiology continues to see benefits in having a product platform under both Signia and Widex brands. Analysts also see benefits. 

For subscribers



Photo: Gn Store Nord / Pr
Hearing health

President of North American operations to lead GN Hearing from October

The future head of GN Hearing will report to Peter Karlströmer, who will become Group CEO in October. 

For subscribers


Jobs

  • Project Director, HR & ESG

  • VP of Software Development, Perfusion Tech

  • Clinical Supply Manager

  • Scientist - Bioanalysis, Biologics

  • Senior Analytical Scientists

  • Qualified Person to AJ Vaccines

  • Clinical Trial Manager

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Senior Legal Councel

  • Director, Head of Antibody Technology

  • Senior QA Specialists (GMP or GCP)

  • Supply Value Stream (SVS) Project Manager

  • Audit & Supplier Manager

  • Global Medical Manager

  • QA/RA Manager

See all jobs

Latest news

  • Investment bank: Novo Nordisk's patent victory is a small victory as price negotiations loom –
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics –
  • Olympus appoints new chief medical officer –
  • Low share price may knock Galecto off the stock exchange –
  • Fujifilm expands management with former Leo executive –
  • Snack maker keeps an eye on Novo Nordisk's obesity drug –
  • FDA approves Novo Nordisk drug to treat rare condition –
  • FDA updates Novo Nordisk's Ozempic drug label with side effect alert –
  • FDA rejects atopic dermatitis drug lebrikizumab –
  • FDA to support new orphan drugs through pilot program –
See all

Jobs

  • Project Director, HR & ESG

  • VP of Software Development, Perfusion Tech

  • Clinical Supply Manager

  • Scientist - Bioanalysis, Biologics

  • Senior Analytical Scientists

  • Qualified Person to AJ Vaccines

  • Clinical Trial Manager

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Senior Legal Councel

  • Director, Head of Antibody Technology

  • Senior QA Specialists (GMP or GCP)

  • Supply Value Stream (SVS) Project Manager

  • Audit & Supplier Manager

  • Global Medical Manager

  • QA/RA Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved